# Infectious Disease Sector

Canonical URL: https://biopharmsignal.com/sector/infectious-disease

Infectious Disease includes companies developing antivirals, antibiotics, vaccines, and other programs aimed at preventing or treating viral, bacterial, or fungal infections. It is a broad category that can span both commercial public health products and early-stage pipeline assets.

Companies currently grouped under Infectious Disease: 9

## Recent Sector News

- 2026-07-20 12:30 EST — VIRI — [Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026](https://biopharmsignal.com/news/VIRI/dogwood-enrolls-first-200-patients-in-ongoing-halneuron-phase-2b-chemotherapy-in-dd9f404d) — Source: Virios Therapeutics
- 2026-06-30 12:45 EST — VIRI — [Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-appoints-iain-dukes-venture-partner-at-orbimed-as-chair-of--8101d663) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — AVIR — [Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-completes-patient-enrollment-in-phase-3-c-forward-trial-evaluating-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus) — Source: Atea
- 2026-06-25 13:46 EST — AVIR — [Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatitis-c-virus-at-easl-congress-2026) — Source: Atea
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-commencement-of-halneuronr-chemotherapy-induced-neuropathic-pain-phase-2b-long-term-extension-study) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-first-quarter-2026-financial-results) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — AVIR — [Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-present-three-abstracts-at-easl-2026-congress-highlighting-progress-across-viral-hepatitis-pipeline) — Source: Atea
- 2026-06-25 13:46 EST — AVIR — [Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Atea
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-to-report-third-quarter-2025-financial-results-on-thursday-november-6-2025) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Reports Third Quarter 2025 Financial Results](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-reports-third-quarter-2025-financial-results) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025](https://biopharmsignal.com/news/VIRI/dogwood-announces-enrollment-of-first-100-patients-in-ongoing-halneuron-r-phase-2b-trial-interim-sample-size-analysis-on-track-for-december-2025) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-files-new-synthetic-halneuron-r-intellectual-property-protection-projected-to-extend-exclusivity-period-up-to-2045) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-positive-interim-phase-2b-clinical-trial-results-in-chemotherapy-induced-neuropathic-pain) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-inc-announces-financing-of-up-to-26-8-million-to-progress-halneuronr-through-phase-2b-development) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-50-enrollment-in-ongoing-halneuronr-phase-2b-trial-top-line-results-anticipated-in-q3-2026) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VIRI — [Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and-neuropathy) — Source: Virios Therapeutics
- 2026-06-25 13:46 EST — VCNX — [Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain](https://biopharmsignal.com/news/VCNX/vaccinex-reports-new-findings-for-signal-ad-phase-1b-2-trial-of-pepinemab-at-clinical-trials-on-alzheimer-s-disease-ctad-conference-in-madrid-spain) — Source: Vaccinex
- 2026-06-25 13:46 EST — VCNX — [Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting](https://biopharmsignal.com/news/VCNX/vaccinex-reports-improved-immunity-correlating-with-clinical-benefit-of-pepinemab-combination-treatment-at-society-for-immunotherapy-of-cancer-s-annual-meeting) — Source: Vaccinex

## Companies

- [AUVI](https://biopharmsignal.com/company/AUVI) — Applied UV
- [ARGS](https://biopharmsignal.com/company/ARGS) — Argos
- [AVIR](https://biopharmsignal.com/company/AVIR) — Atea
- [CDTX](https://biopharmsignal.com/company/CDTX) — Cidara Therapeutics
- [COCP](https://biopharmsignal.com/company/COCP) — Cocrystal Pharma
- [MRNA](https://biopharmsignal.com/company/MRNA) — Moderna, Inc.
- [POAI](https://biopharmsignal.com/company/POAI) — Predictive Oncology
- [VCNX](https://biopharmsignal.com/company/VCNX) — Vaccinex
- [VIRI](https://biopharmsignal.com/company/VIRI) — Virios Therapeutics